PT  - JOURNAL ARTICLE
AU  - Peng Xue
AU  - Li-Li Gao
AU  - Jian Yin
AU  - Li-Li Han
AU  - Jing Zhao
AU  - Li Li
AU  - Samuel Seery
AU  - Xue-Yan Han
AU  - Ting-yuan Li
AU  - Yu Jiang
AU  - Jie Shen
AU  - Wen Chen
TI  - A direct comparison of four high risk human papilloma virus tests versus the cobas test for detecting cervical intraepithelial neoplasia and cervical cancer
AID  - 10.1101/314435
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 314435
4099  - http://biorxiv.org/content/early/2018/05/04/314435.short
4100  - http://biorxiv.org/content/early/2018/05/04/314435.full
AB  - This study is to evaluate performances and genotyping capabilities of four human papilloma virus (HR-HPV) tests based on real-time polymerase chain reaction (PCR) technology platforms compared with the cobas test. Discordant results were further analyzed using INNO-LiPA HPV genotyping test, the gold standard laboratory test to determine presence and type of HPV infection. Over 200 samples from Hospital patients were collected and analyzed using five HR-HPV tests. Women with positive test results were referred directly to colposcopy. If a positive result was returned, biopsies were administered for pathological classification. Clinical performances and genotyping capabilities between the four HR-HPV and cobas tests were compared and contrasted. High levels of agreement were observed, though all HR-HPV tests presented discrepancies compared with the cobas test. Cervical intraepithelial neoplasia Grade 2 or higher lesions (CIN2+) was set as the threshold, and all five tests performed with equally high sensitivity. Lower levels of specificity were observed across all five tests. Results suggest the four HR-HPV tests analyzed are as effective as the cobas test in genotyping capacities and diagnosing CIN. Therefore, these test kits should be used for HPV screening, especially in developing nations because they are cost effective and reliable. Minor discrepancies between tests are generally unavoidable though this may add complexity to the clinical decision-making process. As such, we recommend that efforts be made to standardize HPV genotyping tests as well as to optimize clinical sensitivity and specificity. Focusing on these issues will drive the development of HPV detection techniques, therefore save lives.